Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5030940> ?p ?o }
Showing triples 1 to 69 of
69
with 100 triples per page.
- Q5030940 subject Q16819643.
- Q5030940 subject Q8492996.
- Q5030940 subject Q8567712.
- Q5030940 subject Q8852392.
- Q5030940 subject Q8955377.
- Q5030940 abstract "Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class, used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.".
- Q5030940 atcPrefix "A10".
- Q5030940 atcSuffix "BX11".
- Q5030940 bioavailability "65.0".
- Q5030940 casNumber "842133-18-0".
- Q5030940 chEBI "73274".
- Q5030940 drugbank "DB08907".
- Q5030940 fdaUniiCode "6S49DGR869".
- Q5030940 iupacName "(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol".
- Q5030940 pubchem "24812758".
- Q5030940 thumbnail Canagliflozin.svg?width=300.
- Q5030940 wikiPageWikiLink Q130146.
- Q5030940 wikiPageWikiLink Q130964.
- Q5030940 wikiPageWikiLink Q15318084.
- Q5030940 wikiPageWikiLink Q15318183.
- Q5030940 wikiPageWikiLink Q16775101.
- Q5030940 wikiPageWikiLink Q16819643.
- Q5030940 wikiPageWikiLink Q194290.
- Q5030940 wikiPageWikiLink Q19484.
- Q5030940 wikiPageWikiLink Q200656.
- Q5030940 wikiPageWikiLink Q20089925.
- Q5030940 wikiPageWikiLink Q202758.
- Q5030940 wikiPageWikiLink Q21163221.
- Q5030940 wikiPageWikiLink Q275419.
- Q5030940 wikiPageWikiLink Q28749.
- Q5030940 wikiPageWikiLink Q3025883.
- Q5030940 wikiPageWikiLink Q3041588.
- Q5030940 wikiPageWikiLink Q311213.
- Q5030940 wikiPageWikiLink Q333718.
- Q5030940 wikiPageWikiLink Q410020.
- Q5030940 wikiPageWikiLink Q417765.
- Q5030940 wikiPageWikiLink Q418776.
- Q5030940 wikiPageWikiLink Q419832.
- Q5030940 wikiPageWikiLink Q425027.
- Q5030940 wikiPageWikiLink Q427492.
- Q5030940 wikiPageWikiLink Q4545703.
- Q5030940 wikiPageWikiLink Q6883161.
- Q5030940 wikiPageWikiLink Q7312490.
- Q5030940 wikiPageWikiLink Q824258.
- Q5030940 wikiPageWikiLink Q8492996.
- Q5030940 wikiPageWikiLink Q8567712.
- Q5030940 wikiPageWikiLink Q877827.
- Q5030940 wikiPageWikiLink Q8852392.
- Q5030940 wikiPageWikiLink Q8955377.
- Q5030940 wikiPageWikiLink Q901125.
- Q5030940 wikiPageWikiLink Q903523.
- Q5030940 wikiPageWikiLink Q9368.
- Q5030940 atcPrefix "A10".
- Q5030940 atcSuffix "BX11".
- Q5030940 bioavailability "65.0".
- Q5030940 casNumber "842133".
- Q5030940 chebi "73274".
- Q5030940 drugbank "DB08907".
- Q5030940 iupacName "-2".
- Q5030940 pubchem "24812758".
- Q5030940 unii "6".
- Q5030940 type ChemicalSubstance.
- Q5030940 type Drug.
- Q5030940 type ChemicalObject.
- Q5030940 type Thing.
- Q5030940 type Q8386.
- Q5030940 comment "Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class, used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.".
- Q5030940 label "Canagliflozin".
- Q5030940 depiction Canagliflozin.svg.